Understanding and overcoming major barriers in cancer nanomedicine - PubMed (original) (raw)

Editorial

Understanding and overcoming major barriers in cancer nanomedicine

Shuming Nie. Nanomedicine (Lond). 2010 Jun.

No abstract available

PubMed Disclaimer

Figures

Figure 1

Figure 1. Nanoparticle interactions with plasma proteins and blood immune cells

The main modes of interactions include (A) nonspecific protein adsorption on the particle surface (opsonization) and phagocytosis by leukocytes (e.g., monocytes), (B) nonspecific nanoparticle–cell membrane interactions (electrostatic or hydrophobic) and (C) fluid-phase pinocytosis. Adapted with permission from Aaron Mohs, Nie Group, Emory University, GA, USA.

Figure 2

Figure 2. Quantum dots involved in both active and passive tumor targeting

In the passive mode, nanometer-sized particles such as quantum dots accumulate at tumor sites through an enhanced permeability and retention effect. For active tumor targeting, nanoparticles are conjugated to molecular ligands such as antibodies and peptides to recognize protein targets that are overexpressed on the surface of tumor cells such as the EGF receptor, the transferrin receptor or the folate receptor. Adapted with permission from Ximei Qian, Nie Group, Emory University, GA, USA.

Similar articles

Cited by

References

    1. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5:161–171. - PubMed
    2. ▪ Excellent review article describing the promises and challenges in cancer nanotechnology and nanomedicine.
    1. Riehemann K, Schneider SW, Luger TA, et al. Nanomedicine – challenge and perspectives. Angew Chem Intl Ed. 2009;48:872–897. - PMC - PubMed
    1. Nie SM, Xing Y, Kim GJ, et al. Nanotechnology applications in cancer. Ann Rev Biomed Eng. 2007;9:257–288. - PubMed
    2. ▪ Comprehensive review article summarizing nanotechnology applications in cancer imaging, diagnostics and targeted therapy.
    1. Sanhai WR, Sakamoto JH, Canady R, et al. Seven challenges for nanomedicine. Nat Nanotechol. 2008;3:242–244. - PubMed
    1. Heath JR, Davis ME. Nanotechnology and cancer. Ann Rev Med. 2008;59:251–265. - PMC - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources